Highlights nieuwsbrief 3

This newsletter presents you the following key sessions:

1. Video-interview with Laurie Sehn, MD, PhD, about the results of the phase II trial assessing the efficacy
    and safety of the addition of polatuzumab to bendamustine and rituximab in patients with r/r DLBCL

2. Ixazomib, lenalidomide and dexamethasone for relapsed and refractory multiple myeloma – data
    from the Czech Registry of Monoclonal Gammopathies

3. Ravulizumab shows noninferiority versus eculizumab in adult patients with paroxysmal nocturnal
    haemoglobinuria naive to complement inhibitors

4. Ibrutinib lead-in followed by venetoclax in patients with chronic lymphocytic leukemia: phase II
    CAPTIVATE early safety and efficacy results

5. DESTINY trial: sustained recurrence free survival in the second stopping year